NEW YORK--(BUSINESS WIRE)--May 4, 2021--

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2021 and raised 2021 guidance (3) for revenues and Adjusted diluted EPS (2) driven by the updated expectations for contributions to 2021 performance from BNT162b2, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, as well as the strong performance of the business excluding BNT162b2, partially offset by anticipated additional R&D investments into vaccines to protect against COVID-19, as well as other mRNA-based development programs and COVID-19 antivirals.

Copyright Business Wire 2021.